Company Filing History:
Years Active: 1998
Title: Hidde J Haisma: Innovator in Pharmaceutical Prodrugs
Introduction
Hidde J Haisma is a notable inventor based in Hoevelaken, Netherlands. He has made significant contributions to the field of pharmaceuticals, particularly in the development of prodrugs that enhance the efficacy of cancer treatments. With a total of two patents to his name, Haisma's work is recognized for its innovative approach to drug formulation.
Latest Patents
Haisma's latest patents include advancements in paclitaxel and anthracycline prodrugs. The first patent focuses on a paclitaxel prodrug that features a paclitaxel portion linked to a cleavable N-(aliphatic or aromatic)-O-glycosyl carbamate spacer group. This prodrug can be administered through various methods, including oral, topical, or injection, to achieve an anti-tumor effect. Activation occurs via a hydrolizing enzyme, whether endogenous or exogenous. The second patent details anthracycline derivatives that are also coupled to an enzymatically cleavable N-phenyl-O-glycosyl carbamate spacer group. These derivatives are represented by a specific formula and include the synthesis methods and their applications, either alone or in combination with enzymes or antibody-enzyme conjugates.
Career Highlights
Hidde J Haisma is associated with Pharmachemie B.V., where he continues to innovate in the pharmaceutical sector. His work has contributed to the development of more effective cancer therapies, showcasing his commitment to improving patient outcomes through scientific research.
Collaborations
Haisma has collaborated with notable colleagues, including Ruben G Leenders and Johan W Scheeren. These partnerships have likely enhanced the scope and impact of his research, fostering a collaborative environment for innovation.
Conclusion
Hidde J Haisma stands out as a significant figure in the field of pharmaceutical innovations, particularly in the area of prodrugs for cancer treatment. His contributions through patents and collaborations reflect his dedication to advancing medical science.